Paragonix, an organ transplant company, said it has entered into a definitive agreement to be acquired by Getinge. Getinge said its global reach will expand access of Paragonix’s organ transplant technologies to new markets while also creating opportunities for combining the organ containment and blood perfusion technologies of the two companies for new innovations.
Today, Paragonix is one of the leading U.S. cardiothoracic organ preservation technology provider and is expanding in abdominal transplantation. Paragonix has developed a robust portfolio to meet the needs of the transplant community including leading clinical research initiatives, smart digital logistics platforms, and national clinical services networks. By integrating this leadership in transplantation with Getinge's extensive resources and global distribution network, the acquisition will accelerate the availability of this transformative medical technology. Today’s agreement will also foster the creation of new technologies addressing critical global healthcare needs.
Paragonix last year received FDA clearance for its lung preservation system and this year introduced a pancreas transportation system.
